Key Recommendations from the 2023 Guidelines for Managing Atopic Dermatitis (AD)

1. Topical Treatments:

• Use topical corticosteroids (TCS) or topical calcineurin inhibitors (TCIs) for patients whose AD remains uncontrolled despite regular use of moisturizers.
• Crisaborole 2% ointment is suggested for mild-to-moderate AD.

1. Bleach Baths:

• Recommended as an add-on therapy for patients with moderate-to-severe AD, but not advised for those with mild AD.

1. Elimination Diets:

• Not generally recommended due to unclear benefits and potential risks.

1. Systemic Treatments:

• Biologics like dupilumab and tralokinumab are advised for moderate-to-severe AD.
• Oral JAK inhibitors may be considered in refractory cases, with careful patient selection.

---

References

• Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations [link]